BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced trial results related to RAPIVAB™ (peramivirinjection), a neuraminidase inhibitor (NAI) for the treatment ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE